Navigation Links
Barriers to obtaining gene expression profiling test heightened perceived value
Date:6/17/2014

Barriers to obtaining gene expression profiling test heightened perceived value among patients, new study says TORONTO, June 17, 2014Barriers to obtaining gene expression profiling tests heightened their perceived importance among patients with early breast cancer who were deciding whether to have chemotherapy, a new study says.

Gene expression profiling tests, such as Oncotype Dx, analyze the patterns of 21 different genes within cancer cells to help predict how likely it is that a women's cancer will recur within 10 years after initial treatment and how beneficial chemotherapy will be to her.

Dr. Yvonne Bombard, a genomics and health services researcher in the Li Ka Shing Knowledge Institute of St. Michael's Hospital, found that access to this newly available and expensive technology is subject to careful administration and oversight.

However, she said that has created unintended consequences such as making oncologists gatekeepers for determining when it was medically appropriate for someone to have the test, leading to perceived inequalities in access by patients. Moreover, media attention made patients more aware of the gene expression profiling tests and led them to specifically ask for them, but that complicated physicians' gatekeeping efforts, sometimes hurting the doctor-patient relationship.

"There was a sense that the test was scarce or difficult to obtain, which heightened patients' desire for it and led them to perceive gene expression profiling tests as the deciding factor in their chemotherapy decisions, over and above other clinical tests and indicators," she said.

Dr. Bombard interviewed 14 oncologists and 28 breast cancer patients in Ontario for a study published today in Current Oncology. Ontario was the first province in Canada to fund gene expression profiling tests.

She said the careful oversight required of oncologists to the test created perceived inequities in access among patients. This often occurred in how oncologists discussed the test with their patients. Some oncologists offered the test to all their patients; others only to those who were eligible or where they felt there was uncertainty about the potential value of chemotherapy. Some raised it early in their consultations with patients, others late in the process, leading some patients to feel their doctors had already made the decision to recommend chemotherapy. Dr. Bombard said some patients felt information about the test was not offered to them because of its high cost, $4,000.

"Such delays or omissions in mentioning the test often left patients confused or feeling that something of great value was being withheld," she said.

Some patients said they learned about the tests from media reports describing a lack of funding in Canada that framed the issue as one of inequitable access to a highly effective, game-changing technology. Several of the oncologists said they felt pressured by the media coverage to offer the test to women for whom they knew it would not provide useful information for their decision-making about chemotherapy.

Another barrier was the extra paperwork around the test, which is not performed in Canada. Patients and oncologists must fill out forms to establish eligibility for OHIP reimbursement. Oncologists were then required to obtain government approval before sending tumour samples out of the country for testing. Results usually take about three weeks. This extra paperwork was cumbersome, increased anxieties about missing the window to start treatment and also reinforced the impression that the test was special, because it warranted special attention.


'/>"/>

Contact: Leslie Shepherd
shepherdl@smh.ca
416-864-6094
St. Michael's Hospital
Source:Eurekalert  

Related medicine news :

1. Study identifies barriers to breast health care in Pakistan
2. Kicking the habit -- new research examines the barriers to quitting smoking for smokers with asthma
3. Cultural, social factors identified as barriers to minority participation in stem cell donation
4. Personalized plans to address barriers to HIV drug adherence boost chances of successful therapy
5. Baylor University researchers study barriers, resources to physical activity in Texas towns
6. Affordable care alone may not be enough to help Latinos overcome cancer care barriers
7. Kids on Medicaid May Face Barriers to Eczema Treatment
8. Experts to present data addressing patient and physician barriers to clinical trials
9. BroadConnect Is Offering New Hosted PBX Bundle Pricing for New Customers, Eliminating VoIP Adoption Barriers
10. Research examines how technology can break down barriers
11. Egg-allergic children now have no barriers to flu shot
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Barriers to obtaining gene expression profiling test heightened perceived value
(Date:5/6/2016)... ... 06, 2016 , ... From May 4 to 6, EarQ and ... opportunity to learn more about Signia’s technology and the successful business and marketing techniques ... priority to see practices succeed in this highly competitive industry,” said Ed Keller, president ...
(Date:5/6/2016)... Arizona (PRWEB) , ... May 06, 2016 , ... ... moved domains to Sleepopolis.com . , Since launching in September, 2014 Sleepopolis ... research and testing areas, which now include pillows, sheets, mattress toppers, bed frames, ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... online provider of career-focused education and corporate training, and the National Military Family ... to announce Maritza Aquino as the second full-tuition scholarship recipient of 2016. ...
(Date:5/6/2016)... ... May 06, 2016 , ... RowdMap, Inc. ... Cross BlueShield and Former Principal Deputy Administrator at Centers for Medicare and Medicaid ... Steve Ondra, MD, Chief Medical Officer at Health Care Service Corporation (Blue Cross ...
(Date:5/5/2016)... ... May 05, 2016 , ... Qrono Inc. , ... a development collaboration with the Australian critical medicine company, Phebra Pty Ltd. ... , LAI medicines can offer improved therapeutic benefits over oral formulations, including better ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 2016 Research and Markets has announced ... in the USA"  report to their offering.  ,     (Logo: ... the current Positron Emission Tomography (PET) scanner and cyclotron ... market. Along with the current known number of PET ... , the report also contains a detailed breakdown of ...
(Date:5/5/2016)... 5, 2016 ... of the  "Europe Thrombocytopenia Market and ... to their offering.       ... ,The latest research Europe Thrombocytopenia Market ... provides comprehensive insights into Thrombocytopenia pipeline ...
(Date:5/4/2016)... Conn., May 4, 2016  Compass Diversified Holdings (NYSE: ... "Company"), an owner of leading middle market businesses, announced ... ended March 31, 2016. First Quarter 2016 ... and Reinvestment ("CAD" or "Cash Flow") of $13.6 million ... net loss of $15.0 million for the first quarter ...
Breaking Medicine Technology: